How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Adiponectin (Adp) Elisa Reagents Market
- By Product Type: Sandwich ELISA Kits, Competitive ELISA Kits, Indirect ELISA Kits, Direct ELISA Kits
- By Sample Type: Serum, Plasma, Cell Culture Supernatant, Tissue Homogenate, Urine
- By End User: Clinical Diagnostic Laboratories, Research Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes
- By Application: Diabetes and Metabolic Disorder Research, Cardiovascular Disease Research, Obesity Research, Inflammation and Immune Response Studies, Drug Development and Screening
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Sandwich ELISA Kits leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.166 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.174 →
Full report · locked preview
Everything inside the Adiponectin (Adp) Elisa Reagents Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 4
Sample Type 5
End User 4
Application 5
Companies profiled
R&D Systems (Bio-Techne)
Abcam plc
Thermo Fisher Scientific
Sigma-Aldrich (Merck KGaA)
BioVision Inc.
MyBioSource Inc.
Cusabio Biotech Co. Ltd.
Elabscience Biotechnology Inc.
Cloud-Clone Corp.
RayBiotech Inc.
Invitrogen (Thermo Fisher Scientific)
Enzo Life Sciences Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →R&D Systems (Bio-Techne)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abcam plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sigma-Aldrich (Merck KGaA)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →BioVision Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →MyBioSource Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Cusabio Biotech Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Elabscience Biotechnology Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cloud-Clone Corp.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →RayBiotech Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Invitrogen (Thermo Fisher Scientific)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Enzo Life Sciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Boster Biological Technology
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Wuhan Fine Biotech Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →GenWay Biotech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,185M by 2033 · 8.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Sandwich ELISA Kits42.7
- Competitive ELISA Kits21.0
- Indirect ELISA Kits19.5
- Direct ELISA Kits16.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,260M → $2,628M · 9.6%
Europe$877.8M → $1,777M · 9.2%
Asia Pacific$801.5M → $1,587M · 8.9%
Latin America$496.2M → $1,049M · 9.8%
Middle East and Africa$381.7M → $770.1M · 9.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.182026
8.192027
8.202028
8.212029
8.232030
8.242031
8.252032
8.272033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- R&D Systems (Bio-Techne)15.1
- Abcam plc12.9
- Thermo Fisher Scientific13.5
- Sigma-Aldrich (Merck KGaA)12.0
- BioVision Inc.4.6
- MyBioSource Inc.14.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type10.7%
Sample Type27.5%
End User28.9%
Application32.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.6
- Europe22.8
- Asia Pacific20.3
- Latin America13.4
- Middle East and Africa9.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| R&D Systems (Bio-Techne) | 93 | 93 | 74 | 74 | 96 | 93 | 87 |
| Abcam plc | 76 | 77 | 69 | 74 | 88 | 77 | 77 |
| Thermo Fisher Scientific | 67 | 84 | 85 | 67 | 81 | 85 | 78 |
| Sigma-Aldrich (Merck KGaA) | 65 | 67 | 79 | 63 | 65 | 77 | 69 |
| BioVision Inc. | 60 | 74 | 74 | 64 | 70 | 70 | 69 |
| MyBioSource Inc. | 63 | 64 | 50 | 52 | 69 | 70 | 61 |
| Cusabio Biotech Co. Ltd. | 63 | 63 | 54 | 52 | 60 | 50 | 57 |
| Elabscience Biotechnology Inc. | 54 | 42 | 48 | 54 | 54 | 42 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- R&D Systems (Bio-Techne)
- Abcam plc
- Thermo Fisher Scientific
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| R&D Systems (Bio-Techne) | ✓ | ✓ | ✓ | − | ◐ | ✓ |
| Abcam plc | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Thermo Fisher Scientific | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Sigma-Aldrich (Merck KGaA) | − | − | ◐ | ◐ | ✓ | ◐ |
| BioVision Inc. | − | ◐ | ✓ | ✓ | ◐ | ◐ |
| MyBioSource Inc. | ◐ | ◐ | ◐ | − | ◐ | − |
| Cusabio Biotech Co. Ltd. | ✓ | ✓ | − | − | ◐ | − |
| Elabscience Biotechnology Inc. | ◐ | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1R&D Systems (Bio-Techne)87
2Thermo Fisher Scientific78
3Abcam plc77
4Sigma-Aldrich (Merck KGaA)69
5BioVision Inc.69
6MyBioSource Inc.61
7Cusabio Biotech Co. Ltd.57
8Elabscience Biotechnology Inc.49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
R&D Systems (Bio-Techne)Thermo Fisher Scientific
Challenger3
Strong scale, closing on the leaders.
Abcam plcSigma-Aldrich (Merck KGaA)BioVision Inc.
Contender2
Focused players with pockets of strength.
MyBioSource Inc.Cusabio Biotech Co. Ltd.
Niche1
Specialists in a single segment or region.
Elabscience Biotechnology Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Adiponectin (Adp) Elisa Reagents Market — a $62M beachhead inside a $1.06B market.
Beachhead (SOM)$62Mobtainable near-term
Serviceable (SAM)$367Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Sandwich ELISA Kits
Best fit — highest urgency & budget in Product Type.
Economic buyer76 fit
Competitive ELISA Kits
Strong fit — clear ROI and a fast path to value.
End user68 fit
Indirect ELISA Kits
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Sample Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel29%
Digital / self-serve19%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Adiponectin (Adp) Elisa Reagents Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified26%
Evaluation14%
Closed-won6%
$17.7KCAC
$84KLTV
4.7:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Adiponectin (Adp) Elisa Reagents Market is a high-growth opportunity — $11.1B by 2033, compounding at 10.8%.
TAM · 2025$4.91Btoday
TAM · 2033$11.1Bforecast
CAGR10.8%2027–2033
Cumulative$68.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$11.1BTotal addressable market
SAM$4.08BServiceable available market
SOM$892MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.8% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$11.1BLarge & growingTAM by 2033 at 10.8% CAGR
$4.08BServiceable nowreachable with today’s model
$892MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.68BBear7.0% CAGR
$11.1BBase10.8% CAGR
$14.2BBull14.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Sample Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Adiponectin (Adp) Elisa Reagents Market — a $3.48B market by 2033. Plan: grow share from 7.1% to 11.1%.
Market size · 2033$3.48Btotal addressable
Market CAGR6.1%2027–2033
Target share11.1%from 7.1% today
Revenue ambition$386Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.1% | 11.1% | On track |
| Revenue | $253M | $386M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 29.9% | 41.9% | On track |
| Customer retention | 90.4% | 97.0% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Sample Type capability
A defensible second engine — invest in Sample Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Sample Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $57M capacity & capability investment
- Greenlight bolt-on M&A in Sample Type
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Adiponectin (Adp) Elisa Reagents Market conversation — a $2.47B market you can size, segment and defend in minutes.
Market size · 2033$2.47Btotal opportunity
Growth6.9%CAGR to 2033
Addressable buyers1,738+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 2 mopayback period
$76K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
R&D Systems (Bio-Techne)Abcam plcThermo Fisher ScientificSigma-Aldrich (Merck KGaA)BioVision Inc.MyBioSource Inc.Cusabio Biotech Co. Ltd.Elabscience Biotechnology Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Adiponectin (Adp) Elisa Reagents Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Adiponectin (Adp) Elisa Reagents Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Adiponectin Market
Market size, share, segmentation and regional forecast.
$509M market · 2025 base year
View reportAdipose Stem Cells (Ascs) Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportAdjacent Amide Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportAdjust Oven Temperature Display Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportAdjustable Articulator Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportAdjustable BarberÃÂs Chair Sales Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportAdjustable BarberÃx82Âx92s Chair Sales Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportAdjustable Bone Plate Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportAdjustable Condylar Path Articulators Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportAdjustable Desks Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportAdjustable Divergence Angle Beam Expander Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportAdjustable Dose Electronic Syringe Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.